Wiggin and Dana Represents Rallybio in Series A Financing

April 25, 2018

Wiggin and Dana client Rallybio, a biotechnology company established to identify and accelerate the development of breakthrough therapies for patients with severe and rare disorders, recently announced that it has secured $37 million in Series A funding from investors including 5AM Ventures, Canaan Partners, New Leaf Venture Partners, and Connecticut Innovation.

For more information about this transaction, please click here.